The U.S. Food and Drug Administration approved a new treatment option for psoriasis patients earlier this year: AbbVie’s Skyrizi (risankizumab-rzaa). This medication, which is used as a subcutaneous injection, gained this approval after a series of studies showed a high rate of skin clearance in adults with severe plaque psoriasis using Skyrizi. Ready for even […]

August is National Psoriasis Awareness Month, making it the perfect time to share information about this skin disease and dispel myths associated with it. All in all, there’s a lot that your average patient might be misunderstanding about psoriasis. Click here to get the medications your psoriasis patients need today! Myth #1: That skin rash […]

A substantial percentage of the 7 million Americans with psoriasis experience fatigue as an additional unwelcome bother, along with the better known symptoms of dry, scaly, painful, and itchy patches of skin. Typical locations for psoriasis include the joints, face, neck, trunk, arms, hands, feet, and scalp. There are a variety of medications that a […]

Observing the gait and walking pace of a cancer patient can serve as a sort of shorthand to assess overall patient health and even the chances of optimal treatment outcome. About a decade ago, researchers found that gait speed could be used in a general way to predict which patients might have greater challenges recovering […]

Prescription medications for psoriasis offer patients a better chance than ever before for significant skin clearance of the red, white, or silvery patches on their skin (as well as other potential symptoms, such as itching, nail changes, or cracking skin). There’s never been a better chance than there currently is for so many patients to […]

Taltz (ixekizumab, Eli Lilly), a biologic injection medication for psoriasis, shows a high level of effectiveness and the latest research demonstrates that the clear-skin response which so many patients benefit from when they use Taltz keeps up for at least four years after starting treatment. Taltz first became available in 2016 for moderate to severe […]

Scroll to Top